Company profile: Loxo Oncology
1.1 - Company Overview
Company description
- Provider of targeted cancer therapies for genetically defined patient populations, focused on developing biopharmaceutical treatments and rapidly advancing them into the clinic to achieve outsized clinical effects.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Loxo Oncology
PanTher Therapeutics
HQ: United States
Website
- Description: Provider of localized cancer therapies leveraging the Sagittari platform to optimize drug dose and duration for high-dose, tumor-targeted treatment with minimal systemic exposure. Offers PTM-101, a clinical-stage candidate delivering high concentrations of paclitaxel to pancreatic tumors via minimally invasive laparoscopy, and exploratory programs for pancreatic, colon, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanTher Therapeutics company profile →
Lycia Therapeutics
HQ: United States
Website
- Description: Provider of lysosome-targeting chimeras (LYTAC) technology for developing therapeutics that target and degrade extracellular and membrane-bound proteins for a range of diseases. Offers the LYTAC platform and a discovery pipeline of degraders for autoimmune and inflammatory conditions and cancer, and maintains a strategic collaboration with Lilly focused on immunology and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lycia Therapeutics company profile →
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Affini-T Therapeutics
HQ: United States
Website
- Description: Provider of autologous TCR-T cell therapies targeting oncogenic driver mutations in solid tumors and off-the-shelf bispecific T cell engagers. Offers the TAILOR discovery platform leveraging machine learning and high-throughput screening, TUNE to enhance persistence and functionality via synthetic biology, and THRIVE for optimized manufacturing and gene editing. Conducts clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affini-T Therapeutics company profile →
Symphogen
HQ: Denmark
Website
- Description: Provider of recombinant polyclonal antibody drugs and platforms for disease treatment and prevention. Offers Symplex PCR cloning for antigen-specific antibodies, an antibody discovery and research platform focused on oncology and immuno-oncology, and CMC processes for manufacturing. Pipeline includes Sym013 (pan-HER antibody mixture) and Sym021 (anti-PD-1) with combinations Sym022 (anti-LAG-3) and Sym023 (anti-TIM-3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Symphogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Loxo Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Loxo Oncology
2.2 - Growth funds investing in similar companies to Loxo Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Loxo Oncology
4.2 - Public trading comparable groups for Loxo Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →